Latest Articles

Publication Date
Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women.

Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …

Published: Feb. 1, 2025, midnight
The effect of endometriosis on oocyte quality: mechanisms, diagnosis and treatment.

Endometriosis significantly impacts the physical and mental health of women of reproductive age. While some patients can achieve pregnancy through surgery or in vitro fertilization (IVF), many still struggle with …

Published: Feb. 1, 2025, midnight
The effect of chronic inflammation on female fertility.

Inflammation has key biological roles in the battle against pathogens, and additional key processes in development and tissue homeostasis. However, when inflammation becomes chronic it can become a serious medical …

Published: Feb. 1, 2025, midnight
Laparoscopic Gynecological Procedures Market to Reach USD 61.3 Billion by 2034, Driven by Technologi - PharmiWeb.com

Laparoscopic Gynecological Procedures Market to Reach USD 61.3 Billion by 2034, Driven by Technologi PharmiWeb.com

Published: Jan. 31, 2025, 7:02 p.m.
Mirvie’s RNA Platform Shows Promise in Predicting Severe Fetal Growth Restriction - Femtech Insider

Mirvie’s RNA Platform Shows Promise in Predicting Severe Fetal Growth Restriction Femtech Insider

Published: Jan. 31, 2025, 6:35 p.m.
RMA of New York Expands Fertility Support Services Through Conceive Partnership - Femtech Insider

RMA of New York Expands Fertility Support Services Through Conceive Partnership Femtech Insider

Published: Jan. 31, 2025, 9:45 a.m.
2nd Circ. Sees No Skadden Conflict In Pharma Merger Work - Law360

2nd Circ. Sees No Skadden Conflict In Pharma Merger Work Law360

Published: Jan. 31, 2025, 2:50 a.m.
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.

Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.

Published: Jan. 31, 2025, midnight
Diagnosis of Genital Tuberculosis Unveiled by Utero-Cutaneous Fistula and Superimposed MRSA Infection: A Case Report.

Both tuberculosis and Methicillin-Resistant Staphylococcus Aureus (MRSA) are known to be notorious for causing fistulas due to their characteristics of persis-tent, difficult-to-treat infections that lead to chronic inflammation, abscess formation, …

Published: Jan. 31, 2025, midnight
The NLRP3 activation-related signature predicts the diagnosis and indicates immune characteristics in endometriosis.

Endometriosis (EMS) is a prevalent gynecological disease that leads to chronic pelvic pain and infertility in women of reproductive age. However, the underlying pathogenic genes and effective treatment for EMS …

Published: Jan. 31, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!